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Characterisation of sterol 
biosynthesis and validation of 14α-
demethylase as a drug target in 
Acanthamoeba
Scott Thomson1, Christopher A. Rice  2,3, Tong Zhang1, RuAngelie Edrada-Ebel  1, Fiona L. 
Henriquez2 & Craig W. Roberts  1
The soil amoebae Acanthamoeba causes Acanthamoeba keratitis, a severe sight-threatening infection 
of the eye and the almost universally fatal granulomatous amoebic encephalitis. More effective 
treatments are required. Sterol biosynthesis has been effectively targeted in numerous fungi using 
azole compounds that inhibit the cytochrome P450 enzyme sterol 14α-demethylase. Herein, using Gas 
Chromatography Mass Spectrometry (GCMS), we demonstrate that the major sterol of Acanthamoeba 
castellanii is ergosterol and identify novel putative precursors and intermediate sterols in its production. 
Unlike previously reported, we find no evidence of 7-dehydrostigmasterol or any other phytosterol 
in Acanthamoeba. Of five azoles tested, we demonstrate that tioconazole and voriconazole have the 
greatest overall inhibition for all isolates of Acanthamoeba castellanii and Acanthamoeba polyphaga 
tested. While miconazole and sulconazole have intermediate activity econazole is least effective. 
Through GCMS, we demonstrate that voriconazole inhibits 14α-demethylase as treatment inhibits the 
production of ergosterol, but results in the accumulation of the lanosterol substrate. These data provide 
the most complete description of sterol metabolism in Acanthamoeba, provide a putative framework 
for their further study and validate 14α-demethylase as the target for azoles in Acanthamoeba.
Acanthamoeba is a genus of normally free-living amoeba found in the environment throughout the world. 
Amoebozoa are single celled organisms and are generally believed to be phylogenetically close to fungi and meta-
zoans, together forming the Amorphea1. Acanthamoeba are mixotrophic and have the ability to encyst when 
the environment becomes hostile. Acanthamoeba can be a facultative pathogen with the ability to cause serious 
infections. The most common of these is Acanthamoeba keratitis (AK) that can lead to corneal damage and even-
tual blindness. Clinical cases of AK are most commonly found in contact lens wearers or following trauma to the 
eye. It is estimated that AK occurs in 1 in 30,000 contact lens wearers in the UK2. Acanthamoeba can also be an 
opportunistic pathogen causing granulomatous amoebic encephalitis (GAE) in people with suppressed immune 
systems.
Treatment of AK is currently arduous and extremely difficult for the patient requiring hospitalisation due 
to the requirement for alternating eye drops containing either propamidine isethionate and polyhexamethyl 
biguanide, or propamidine isethionate and neomycin to be applied on an hourly basis for prolonged periods. 
To compound matters resistance to polyhexamethyl biguanide is developing3, 4. An additional problem is that 
many drugs do not work so well against cysts or even induce Acanthamoeba to encyst. GAE is almost always fatal 
despite extreme measures including multiple drug combinations combined with surgical procedures or cryo-
therapy. A potential exploitable difference between Acanthamoeba and their human host is sterol metabolism. 
While the principal membrane sterol in humans is cholesterol, previous studies have reported that ergosterol and 
7-dehydrostigmasterol as the major sterols of Acanthamoeba5. Furthermore, sterol metabolism has been success-
fully targeted to treat a number of fungal infections of humans. Notably, a number of azole antifungal drugs are 
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known to curtail sterol production through the inhibition of sterol 14α-demethylase. While this would have the 
obvious effect of reducing the integrity of Acanthamoeba membranes alternative mechanisms of action include 
the build up of toxic precursors of ergosterol. It is encouraging that a number of azoles designed to target fungal 
sterol 14α-demethylase have proven effective in treatment of patients with Acanthamoeba infections6–9.
This study was initiated to characterise the sterol composition of Acanthamoeba and correlate this with infor-
mation in the transcriptome project to construct a scheme for sterol biosynthesis in this organism as well as deter-
mine the susceptibilities of a number of A. castellanii and A. polyphaga strains to a variety of azoles (econazole, 
miconazole, sulconazole, tioconazole and voriconazole) using a previously described AlamarBlue assay10, 11. We 
demonstrate that ergosterol as previously reported is the major sterol of Acanthamoeba, but find no evidence of 
7-dehydrostigmasterol as previously reported5 and through the use of GCMS provide the first direct evidence that 
voriconazole inhibits 14α-demethylase in Acanthamoeba.
Results
Ergosterol is the major sterol of Acanthamoeba. GCMS was used to determine the sterol compo-
sition of A. castellanii (Neff strain) and a T4 clinical strain. Ergosterol was the major sterol product detected 
in both strains of A. castellanii. We found no evidence of cholesterol, demosterol, campesterol, stigmasterol or 
7-dehydrostigmasterol in either strain (Fig. 1 and Supplementary data). We found a number of canonical ergos-
terol precursors including lanosterol, 4,4-dimethyl-cholesta-8,14,24-trienol, 4-methyl-zymosterol carboxylate, 
5,7,24(28)ergostatrie-3-enol and 5,7,22,24(28)ergostatetra-3-enol. We did not detect 14-demethyl lanosterol, 
however 4,4 dimethyl cholesta-8-ene, which is a likely reversible intermediate derivative of 14-demethyl lanos-
terol was readily detected. The interconversion between 14-demethyl lanosterol and 4,4 dimethyl cholesta-8-ene 
can occur by simultaneous dehydrogenation (oxidation) and reduction at C-24 and C-25 olefinic bond. We did 
not detect 3-keto-4-methyl-zymosterol, 4-methyl-zymosterol, zymosterol, fecosterol or episterol. However, we 
detected a number of non-canonical sterols suggesting that sterol biosynthesis occurs in Acanthamoeba by a 
modified alternative putative pathway that involves the sequential demethylation and desaturation of lanosterol to 
5,7,9(11),22,24-ergostapenta-3-enol, which is then oxidised to 5,7,9(11),22,24-ergostapenta-3-enone (candidate 
enzymes are ELR12281 and ELR22222, respectively). This would then be reduced to 5,7,22,24(28)-ergostatet-
ra-3-enone (3 possible candidate enzymes are ELR17146, ELR23035 or ELR14820) by losing the 9(11) double 
bond then converted to 4-methylzymosterol carboxylate via a C-4 methyl sterol oxidase (candidate ELR23089) or 
to zymosterol via a reductase (candidate enzyme ELR23089).
We also detected 5,7,24(28)-ergostatrie-3-enone, 5,7,22,24(28)-ergostatetra-3-enone and 
5,7,9(11),22,24(28)-ergostapenta-3-enone which are oxidised forms of episterol, 5,7,24(28)ergostatrie-3-enol 
and 5,7,22,24(28)ergostatetra-3-enol, respectively. Again, we have identified candidate enzymes from the 
Acanthamoeba genome for the reversible oxidation (ELR17146 or ELR23035 or ELR14820) and reduction 
(ELR23089) of these intermediates. The entire proposed scheme is detailed in Fig. 2. The candidate enzymes, 
their current annotation in the Acanthamoeba transcriptome and the names of their fungal and land plant equiv-
alents are listed in Table 1. PCR and sequencing was used to confirm 14α-demethylase in A. polyphaga (ATCC 
50371), A. castellanii (ATCC 50370) and A. castellanii (Neff). These data show no significant differences between 
the nucleotide or predicted amino acid sequences of the strains examined or with the previously available A. 
castellanii (Neff) strain sequences from the transcriptome project (Accession numbers KP970621.1, KP970620.1 
and KP970619.1).
Comparative susceptibilities of Acanthamoeba castellanii and Acanthamoeba polyphaga iso-
lates to a selection of azoles. The growth of 5 different isolates of Acanthamoeba species (A. castellanii: 
T4 clinical isolate, ATCC 50370, Neff strain; A. polyphaga: ATCC50371 and CCAP 1501/18) was assessed at 
24 hours and 96 hours in the presence of five different azoles (econazole, miconazole, sulconazole, tioconazole 
and voriconazole), using a modified AlamarBlue microtiter plate assay as described by McBride et al.10. A repre-
sentative set of dose response curves, depicting voriconazole treatment of the Acanthamoeba isolates is shown in 
Fig. 3. Data for all azoles tested is shown in Table 2. At 24 hours econazole had no effect on the growth of any of 
the Acanthamoeba tested, whereas miconazole and sulconazole only inhibited ATCC 50370 (IC50s 47.7 µM ± 3.5; 
46.85 µM ± 6.23, respectively) at 24 hours and tioconazole inhibited ATCC 50370 and ATCC 50371 (IC50s 
66.66 µM ± 12.12; 8.5 µM ± 1.1, respectively). On the other hand, at 24 hours voriconazole inhibited all isolates 
with exception of A. castellanii Neff strain (Fig. 2E). All azoles tested inhibited Acanthamoeba growth at 96 hours 
(Table 2).
GCMS demonstrates voriconazole specifically inhibits 14-α -demethylase. As the drug assay 
demonstrated that voriconazole was the most effective of the drugs tested, being shown to be capable of inducing 
actual cell death as compared to stasis its method of action was confirmed via GCMS. Lanosterol was undetect-
able in untreated Acanthamoeba at all time points examined, but accumulated to detectable levels cells treated 
with voriconazole at concentrations equivalent to a concentration that inhibited 50% of Acanthamoeba growth 
(IC50) (Fig. 4). In contrast 4,4-dimethyl-cholesta-8,14,24-trienol, a downstream product of 14α-demethylase was 
abundantly detected in non-treated control cultures, but not voriconazole-treated cultures (data not shown). 
Ergosterol levels were reduced in voriconazole treated cultures relative to control cultures at all time points exam-
ined (Fig. 4). These results therefore demonstrate that voriconazole inhibits Acanthamoeba 14α-demethylase and 
results in inhibition of ergosterol production.
Discussion
Treatments for diseases caused by Acanthamoeba are far from ideal and rely on a combination of drugs that 
have shown some efficacy normally in historical or recent clinical cases. In cases where chlorhexidine resistant 
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Acanthamoeba have been encountered topical voriconazole has been used7. There have also been case reports of 
successful treatment of AK and GAE patients using orally administered voriconazole6–9, 12. The choice of azole 
used in each of these cases is not based on laboratory or clinical controlled studies, but rather some positive 
Figure 1. Ion chromatogram demonstrating the principal sterols of Acanthamoeba (clinical T4 strain), their 
retention times (RT), molecular weights (MW) with observed base peaks, chemical formulae, names and 
structures. The structures on column 4 represent the ‘fragment ion peak’, while the structure on column 5 
represent the ‘molecular ion peak’. The fragment ion peak is the base peak which confirms the positions of the 
double bonds on rings B and C, this information is combined with the molecular ion peak to elucidate the 
complete structures.
www.nature.com/scientificreports/
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outcomes. Clearly laboratory studies have the ability to inform clinical studies and have the potential to improve 
treatments. Previous studies have examined relatively few azoles against relatively few isolates of Acanthamoeba 
making direct comparisons and generalisations regarding efficacy difficult13, 14. The situation is further com-
pounded by the use of diverse laboratory assay systems previously in common use. Stepping back from these 
empirical studies, there have been relatively few studies of sterol biosynthesis in Acanthamoeba and those avail-
able hampered by the technologies available at the time. Nonetheless there are a number of intriguing aspects of 
the sterol composition reported in the literature. Firstly, Acanthamoeba castellanii (Neff strain) was reported to 
have 7-dehydrostigmasterol (60%) and ergosterol (40%) as its major sterols, using infrared and ultraviolet spec-
troscopy gas chromatography and mass spectral analysis5. A further study found that Acanthamoeba culbertsoni 
in addition to 7-dehydrostigmasterol and ergosterol also had stigmasta-5,7,22,25-tetraene-3β-ol and stigmasta-5, 
7,14,22,25-pentaene-3β-ol15. The availability of modern GCMS techniques, a microtitre inhibition assay and the 
recent availability of the Acanthamoeba transcriptome project provides an opportunity to address the aforemen-
tioned shortcomings in knowledge10, 16.
GCMS was first used to determine the major sterol composition of Acanthamoeba castellanii (Neff strain) 
and a recently isolated A. castellanii clinical T4 isolate described by Mattana et al.17. The results demonstrate 
that the sterol composition is conserved between the two strains examined. We find that ergosterol is the major 
end product of sterol biosynthesis in Acanthamoeba in contrast with previously published work that reported 
the phytosterol 7-dehydrostigmasterol as the major sterols. In fact, we find no evidence of any of the phytoster-
ols, including 7-dehydrostigmasterol, in Acanthamoeba. Moreover, using GCMS we have identified a number 
canonical putative precursors of ergosterol as well as a number of non-canonical precursors. Interrogation of the 
transcriptome project has allowed us to propose a hypothetical pathway for sterol biosynthesis in Acanthamoeba 
that incorporates the sterols identified by GCMS. This pathway has elements of the canonical pathway, but also 
contains elaborations that ultimately feed back into the canonical pathway to provide putative alternative routes 
to ergosterol. Future studies, potentially using labelled precursors will be necessary to test the unique aspects of 
this candidate pathway. We have interrogated the transcriptome project for Acanthamoeba and have identified a 
set of putative predicted genes that we propose provide the means to produce the identified sterols.
In addition, through testing a number of azoles against a set number of isolates of A. castellanii and A. poly-
phaga we establish that there are relatively small differences between A. castellanii and A. polyphaga isolates in 
their susceptibility to specific azoles. Consistent with this we demonstrate that the assumed target of these azoles 
14α-demethylase is well conserved between all 5 isolates examined. However, we demonstrate that voriconazole 
is far superior to the other azoles tested as it inhibits parasite growth earlier (at 24 hours) and at lower concen-
trations. The superior effects of voriconazole are consistent with a previous report that demonstrated this azole 
Figure 2. Proposed scheme of sterol biosynthesis in Acanthamoeba. Products and intermediates in black were 
identified by GCMS while those in grey were not. Candidate enzymes, named according to their GenBank 
Accession numbers, are annotated in red. **Denotes that this protein is not an enzyme but an anchor protein.
www.nature.com/scientificreports/
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and itraconazole were superior to fluconazole in inhibiting A. castellanii and A. polyphaga in vitro18. Importantly, 
this study also noted that voriconazole and itraconazole had lower dissociation constants for Acanthamoeba 
14α-demethylase than fluconazole18. The results from previous studies that found voriconazole to have an IC50 of 
1.24 µM and 7.16 µM against a variety of Acanthamoeba species are also broadly consistent with the ranges found 
in this study6, 19. The fact that voriconazole has also been reported to show efficacy against cysts over a period of 
7 days is encouraging20.
Although the above studies strongly imply that 14α-demethylase is the target of voriconazole in Acanthamoeba 
this had not been formally demonstrated. Furthermore, target validation of this enzyme, or any other for that 
matter, would normally be achieved through gene-deletion experiments which are not currently possible in 
Acanthamoeba as it is highly polyploid. Thus we employed GCMS to determine the mode of action of voricona-
zole. Our results demonstrate that voriconazole at IC50 levels significantly inhibits the production of ergosterol 
biosynthesis and the ergosterol intermediate 4,4-dimethyl-cholesta-8,14,24 trienol in Acanthamoeba. In addition, 
lanosterol, the substrate for 14α-demethylase and an ergosterol precursor accumulated in voriconazole treated 
Acanthmoeaba. These observations validate 14-α-demethylase as the target of voriconazole.
Overall the multidisciplinary studies described herein, making use of the Acanthamoeba transcriptome, ana-
lytical GCMS and functional cellular assays yield the most comprehensive description of sterol biosynthesis and 
composition in Acanthamoeba to date and a candidate biosynthetic pathway for future validation. The results 
demonstrate the potential benefits of testing diverse azoles in Acanthamoeba and the GCMS technique described 
herein provides the means to verify their mode of action in Acanthamoeba.
Materials and Methods
Acanthamoeba strains and culture conditions. Five isolates of Acanthamoeba spp. were used for com-
parative results. An Acanthamoeba castellanii of the T4 genotype isolated from a case of Acanthamoeba kera-
titis (referred to A. castellanii T4 clinical) was donated by Dr. Antonella Mattana (Sassari, Italy). A. castellanii 
(Neff) was originally obtained from Dr Keith Vickerman (Glasgow, United Kingdom). A. castellanii ATCC 50370 
and Acanthamoeba polyphaga ATCC 50371, American clinical keratitis isolates, were originally obtained from 
the American Type Culture Collection (ATCC, United States) and A. polyphaga CCAP 1501/18 was originally 
obtained from the Culture Collection of Algae and Protozoa (CCAP, United Kingdom).
All strains were maintained by biweekly passages in 10 ml of Protease Peptone-Glucose Media containing 
Protease Peptone (Sigma, UK), 15 g/litre; glucose (Alfa Aesar, UK), 15 g/litre; Potassium phosphate monoba-
sic (Sigma, UK), 330 mg/litre; Thiamine (Sigma, UK), 1 mg/litre; L-methionine (Sigma, UK), 14.9 mg/litre; B12 
(Sigma, UK), 8.33 µg/litre; Biotin (Sigma, UK), 16.66 µg/litre additionally 1 ml/litre of a separate salt solution 
containing calcium chloride (Sigma, UK), 1.5 g/litre; Iron (III) chloride (Sigma, UK), 200 mg/litre; magnesium 
sulfate heptahydrate (Sigma, UK), 24.6 g/litre, had to be added separately. The media of isolates Neff, Clinical T4 
and ATCC 50370 were supplemented with 100 I.U./mL penicillin and 100 (μg/mL) streptomycin (Sigma, Poole, 
United Kingdom). Unless stated otherwise all isolates were grown at room temperature in 75 cm2 tissue culture 
flasks (Corning, Amsterdam, The Netherlands).
Enzyme name EC
Current annotation in Acanthamoeba 
transcriptome
Confirmation by 
PCR
Fungal 
equivalent
Land plant 
equivalent
ELR10814 Lanosterol synthase 5.4.99.7/5.499.8 (Possible bifunctional) cycloartenol synthase ERG7 CAS1
ELR12281 Sterol C-14 α demethylase (CYP51) 1.14.13.70 Obtusifoliol 14 α demethylase (CYP51)
A. castellanii Neff 
KP970619
ERG11 CYP51G1A. polyphaga 50371 KP970621
A. castellanii 50370 
KP970622
ELR20058 Sterol C-14 reductase 1.3.1.70/1.3.1.71 Similarity 7-dehydrocholesterol reductase
A. castellanii Neff 
KP970617
ERG4/24 FK
A. polyphaga 50371 
KP970618
ELR17146; ELR23035; 
ELR14820 C4 methyl sterol oxidase 1.14.13.72 methyl sterol monooxygenase ERG25 SMO1
ELR20134; ELR21498; 
ELR16309; ELR24261
Sterol-4α carboxylate 3 
dehydrogenase 1.1.1.170
UDP glucose 4 epimerase; 3 beta 
hydroxysteroid dehydrogenase; NAD 
dependent epimerase/dehydratase
A. castellanii Neff 
KP970622
ERG26 AT3BETAHSD
A. polyphaga 50371 
KP970623
ELR23089 3-keto steroid reductase 1.1.1.270 NADPH-dependent carbonyl reductase family protein ERG27
ELR15239; ELR23168** ER anchoring ERG28; ERG28 family protein ERG28
ELR14527 SAM C-24 sterolmethyltransferase 2.1.1.41 sterol 24c-methyltransferase ERG6 SMT1
ELR12353 C-8 sterol isomerase 5.-.-.- C-8 sterol isomerase ERG2 HYD1
ELR22222 C-5 sterol desaturase 1.14.19.20 delta7-sterol 5-desaturase ERG3 STE1
ELR23699 C-22 sterol desaturase 1.14.14.- Sterol C22 desaturase-like, putative ERG5
Table 1. Candidate Enzymes involved in sterol biosynthesis in Acanthamoeba.
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GC-MS sample preparation. 8 × 106 Acanthamoeba were pelleted by centrifugation at 1,200 g for 5 min-
utes. The media was then discarded and 5 ml of a 1/1 chloroform/(90% methanol, 10% water) mix was added. 
The cells were then transferred to a clean glass vial and left overnight at 4 °C. The cells were homogenised and 
the lower chloroform containing layer of approximately 2.5 ml was transferred to a clean glass tube. Additional 
chloroform was then added and the cells homogenised again, this was repeated twice more accounting for a total 
of 10 ml of chloroform being extracted. The chloroform solvent was then evaporated and the lipids reconstituted 
with 500 µl of chloroform prior to being analysed.
Figure 3. Representative dose response curves, showing the effect of voriconazole on 5 Acanthamoeba isolates 
(clinical T4, ATCC 50370, Neff, ATCC 50371 and CCAP 1501/18).
www.nature.com/scientificreports/
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The presence of steroids was analysed on a Thermo Finnigan Polaris Plus GCMS. Initial temperature was at 
100 °C, initial time of 1.00 min, with 1 ramp at a rate of 20.0 deg/min to a final temperature of 320 °C. EIMS is set 
at detector voltage of 500.0 V with a source temperature of 220 °C while the GC interface temperature is at 220 °C 
with an emission current of 150 µV. Full scan acquisition is at 2.5 scans per second where the scan range starts 
at 40 amu to end at 650 amu. Syringe volume is at 10 µl. The column was a Factory FourTM capillary (VF-1ms 
30 m × 0.25mm, 0.25 µm). Compounds were identified with NIST online database library.
Bioinformatical analysis. Genes encoding the enzymes belonging to the sterol synthesis pathway were 
identified in GenBank™ (http://www.ncbi.nlm.nih.gov/genbank) both by word search (specific enzyme name 
AND Acanthamoeba), verified in amoebaDB21 and BLASTx for those enzymes not yet specifically identified 
in the Acanthamoeba genome/transcriptome using combination of Saccharomyces cerevisiae and Arabidopsis 
thaliana sterol pathway enzymes. The pathway was constructed using the KEGG metabolic pathway (http://www.
genome.jp/kegg/pathway/map/map00100.html).
PCR for 14α-demethylase. RNA was extracted and complementary DNA was synthe-
sised as described in ref. 22. Oligonucleotides (5′ CCTCCATCTTCTGAATCTGTCGAGG 3′ and 5′ 
GGTGTGATTGCTCACGTTCGCCTTC 3′) were designed using PCR primer tool in Genbank and they were 
synthesised commercially by Life Technologies Ltd. (Paisley, UK). Automated sequencing was performed com-
mercially by Source Bioscience (Nottingham UK).
Time:
24 
Hours
96 
Hours
IC90 
(µM)
SEM 
( ± )
IC50 
(µM)
SEM 
( ± )
IC90 
(µM)
SEM 
( ± )Isolate:
IC50 
(µM)
SEM 
( ± )
Clinical T4 * — * — * — * —
ATCC 50370 * — * — 90.64 22.87 * —
ATCC 50371 * — * — * — * —
Neff * — * — 140.27 8.61 197.14 28.28
CCAP 1501/18 * — * — 104.39 18.9 274.1 16.29
Clinical T4 * — * — * — * —
ATCC 50370 * — * — 8.28 0.12 * —
ATCC 50371 * — * — 21.17 6.05 33.4 6.99
Neff * — * — * — * —
CCAP 1501/18 * — * — 13.42 3.31 28.25 0.7
Clinical T4 * — * — 24.43 5.07 40.97 4.91
ATCC 50370 * — * — 11.48 3.58 47.13 27.44
ATCC 50371 5.53 3.45 18.36 7.43 15.09 11.81 21.36 14.71
Neff * — * — 15.13 6.58 23.79 6.77
CCAP 1501/18 * — * — 4.70 0.64 34.06 23.84
Clinical T4 30.84 18.5 102.22 9.05 13.04 3.94 76.05 37.41
ATCC 50370 12.10 6.16 * — 3.43 0.12 18.72 2.26
ATCC 50371 5.57 1.75 42.66 6.87 5.38 2.94 30.13 23.99
Neff * — * — 8.23 0.44 18.55 2.89
CCAP 1501/18 * — * — 4.63 0.84 18.46 6.41
Clinical T4 * — * — 1.91 0.43 7.57 1.54
ATCC 50370 1.05 0.069 18.27 0.96 0.54 0.001 2.46 0.08
ATCC 50371 0.64 0.36 4.6 3.11 0.98 0.57 1.68 0.8
Neff * — * — 2.1 0.03 4.46 1.15
CCAP 1501/18 0.82 0.24 3.28 0.26 0.92 0.16 2.15 0.5
Table 2. IC50 and IC90 values for the azoles screened against various Acanthamoeba strains at 24 and 96 hours. 
*IC50 or IC90 value was not consistently obtained within the range of concentrations tested.
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Drug Preparation. The majority of the drugs used required individual methods of preparation to ensure 
that a known concentration was in solution. Econazole (Sigma, UK) was dissolved at 112.43 mM in 1:1 chloro-
form:methanol solution. This was then diluted in PG media at 1 in 200 to give a stock solution of 562 µM. The 
preparation of miconazole and sulconazole (all from Sigma, UK) was identical. Drugs were dissolved in DMSO 
(Sigma, UK), to give a concentration of 208.70 mM for miconazole and 217 mM for sulconazole. These solu-
tions were diluted in PG media to give concentrations of 3.339 mM and 3.472 mM, respectively. Residual drug 
was solubilised by adjusting the pH with HCl and the final concentration adjusted to 104 µM and 109 µM. 
Tioconazole (Sigma, UK) was dissolved in DMSO (Sigma, UK) at 500 mM and diluted in PG media to give 
16 mM. Residual drug was solubilised by addition of HCL before diluting in PG to give a final concentration of 
250 µM. Voriconazole was dissolved in DMSO at 28.63 mM and diluted in PG media to 143 µM. The final formu-
lation of each drug was adjusted where necessary to pH 7.0.
AlamarBlue Assay. The AlamarBlue, resazurin assay was carried out as previously described10. Seeding den-
sities for each of the isolates at each of the time points was determined empirically as previously described. Each 
drug was tested over a wide range of concentrations for efficacy against the 5 Acanthamoeba isolates at 23.3 °C 
for 24 hours or 96 hours. Six hours prior to the end of the incubation period 10 μl of AlamarBlue reagent (Abd 
Serotec, UK) was added to all wells except wells that act as a blank. The plate was then incubated for a further six 
hours at 23.3 °C in the dark. Controls consisted of a media blank, trophozoites with media alone, trophozoites 
with the highest concentration of solvent found in the drug samples, trophozoites with 12.5 μM chlorhexidine and 
media with the highest concentration of drug alone. The final volume for all wells was 100 μl.
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